Skip to main content
. 2024 Feb 21;11(1):149–165. doi: 10.1007/s40801-023-00407-w

Table 2.

CTEPH risk factors, symptoms, hemodynamics, and functional class at initial visit or diagnosis

Characteristic Patients (N = 212)
Risk factors for CTEPH documented at initial visita, n (%)
 VTE 89 (42)
 Antiphospholipid antibody syndrome 29 (14)
  Antiphospholipid antibodies 25 (12)
  Lupus anticoagulant 11 (5)
 Thyroid hormone replacement therapy 10 (5)
 Large thrombus mass 9 (4)
 Splenectomy 6 (3)
 Elevated plasma concentrations of factor VIII 3 (1)
 Ventriculoatrial shunt 0 (0)
 Infected pacemaker 0 (0)
 None 52 (25)
 No assessment of risk factors 49 (23)
Symptoms documented at diagnosis/initial visita, n (%)
 Shortness of breath 196 (92)/155 (73)
 Fatigue 90 (42)/83 (39)
 Edema 74 (35)/49 (23)
 Chest discomfort 63 (30)/52 (25)
 Cyanosis 24 (11)/24 (11)
 No symptoms documented 1 (< 1)/10 (5)
History of VTE, n (%) 145 (68)
Length of hospitalization for past VTE before initial visit (days), mean ± SD 22 ± 51 (n = 64)
Time between symptoms and diagnosis (years), mean ± SD 2.2 ± 3.0
6MWD (m), mean ± SD 337.1 ± 118.1
Hemodynamic values at diagnosis, mean ± SD
 RAP (mmHg) 12.9 ± 11.0 (n = 123)
 CO (L/min) 4.0 ± 1.5 (n = 109)
 CI (L/min/m2) 2.3 ± 0.7 (n = 104)
 PCWP (mmHg) 11.7 ± 5.4 (n = 133)
 mPAP (mmHg) 52.7 ± 16.3 (n = 149)
 PVR (WU) 10.5 ± 7.8 (n = 111)
WHO functional class, n (%)
 Not assessed 32 (15)
 I 23 (11)
 II 59 (28)
 III 84 (40)
 IV 14 (7)

Percentages are for all 212 patients unless indicated

6MWD 6-minute walk distance, CI cardiac index, CO cardiac output, CTEPH chronic thromboembolic pulmonary hypertension, mPAP mean pulmonary arterial pressure, PCWP pulmonary capillary wedge pressure, PVR pulmonary vascular resistance, RAP right atrial pressure, SD standard deviation, VTE venous thromboembolism, WHO World Health Organization, WU Wood unit

aMultiple ethnicity, risk factors, or symptoms could be reported